CPPIB-led consortium completed the $80.3m Series B financing round in Sigilon Therapeutics.

CPPIB-led consortium completed the $80.3m Series B financing round in Sigilon Therapeutics, a biotech company. Longevity Vision Fund and funds managed by BlackRock joined founding investor Flagship Pioneering and other existing investors, including Eli Lilly and Company, in the financing round, which brings Sigilon’s total funding to more than $195m. “Our Shielded Living Therapeutics platform is designed to give patients who have chronic diseases a convenient, safe, long-term therapeutic benefit. We believe encapsulating engineered human cells in our proprietary matrix will enable us to deliver controlled doses of therapeutic proteins without the need for immunosuppression and without the risks associated with modifying patients’ genomes. We are pleased to welcome an exceptional group of investors who share our vision of offering more hope and less fear to patients and their caregivers as we enter the clinic with our lead program and continue to advance our other programs toward the clinic,” Rogerio Vivaldi, M.D., Sigilon President and CEO.